Skip to content
DataLookout
Menu

NCT07932691

Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative Colitis

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety and tolerability
Timeframe: First dose up to last follow-up visit (Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration)
Peak Serum Concentration (Cmax)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration.
Time to Peak Concentration (Tmax)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration.
Area Under the Serum Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-t)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Area Under the Serum Concentration-Time Curve from Time Zero to Infinity (AUC0-∞)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Terminal Elimination Rate Constant (λz)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Terminal Elimination Half-Life (t1/2z)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Clearance (CLz)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Trough Concentration at Steady State (Cmin,ss / Ctrough,ss)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Area Under the Curve over One Dosing Interval at Steady State (AUC0-τ,ss)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Average Concentration at Steady State (Cav,ss)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Degree of Fluctuation (DF)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Swing
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Apparent Volume of Distribution at Steady State (Vss/F)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Apparent Clearance at Steady State (CLss/F)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Percentage of AUC Extrapolated to Infinity (AUC_%Extrap)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Mean Residence Time to Infinity (MRT0-∞)
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Accumulation Ratio Based on Cmax (Ra(Cmax))
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Accumulation Ratio Based on AUC (Ra(AUC))
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
Immunogenicity
Timeframe: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration

Secondary (8)

Pharmacodynamics
The modified Mayo score
The endoscopic subscore
The Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
The partial modified Mayo score (excluding endoscopy)
Show 3 moreShow less
The Bowel Disease Questionnaire (IBDQ) score
C-reactive protein (CRP)/high-sensitivity CRP (hs-CRP)
Fecal calprotectin (FC)

Arms and interventions

Recombinant human interleukin-2 fusion protein with human serum albumin (VDJ010) InjectionExperimental
PlaceboPlacebo comparator

Drugs: Recombinant Human Interleukin-2 Fusion Protein with Human Serum Albumin (VDJ010), Placebo

Sites

6 sites in 1 country